Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.

Registrieren

OGN

Organon (OGN)

Organon and Co

Von:

Regulatory News

Text Search:

Sortieren nach:

Non-Regulatory News

Showing the most relevant articles for your search:NYSE:OGN

1 2 3 4 5 6 7 8 9 10 Next >>

Datum	Zeit	Quelle	Überschrift	Symbol	Firma
23/12/2024	12h01	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:OGN	Organon and Co
19/12/2024	13h30	Business Wire	Organon To Present at the 43rd Annual J.P. Morgan Healthcare Conference	NYSE:OGN	Organon and Co
16/12/2024	13h30	Business Wire	FDA Approves VTAMA® (tapinarof) cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older	NYSE:OGN	Organon and Co
06/12/2024	22h15	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:OGN	Organon and Co
05/11/2024	13h40	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:OGN	Organon and Co
05/11/2024	13h29	Business Wire	Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older	NYSE:OGN	Organon and Co
01/11/2024	13h06	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NYSE:OGN	Organon and Co
31/10/2024	13h40	Business Wire	米国FDAが、PROLIA/XGEVA（デノスマブ）のバイオシミラー候補HLX14の生物学的製剤承認申請（BLA）を受理	NYSE:OGN	Organon and Co
31/10/2024	13h39	Business Wire	US-amerikanische FDA akzeptiert BLA für HLX14 – den Biosimilar-Kandidat zu PROLIA/XGEVA (Denosumab)	NYSE:OGN	Organon and Co
31/10/2024	13h39	Business Wire	美國FDA接受PROLIA/XGEVA（地諾單抗）生物學名藥候選藥物HLX14的生物製品授權申請(BLA)	NYSE:OGN	Organon and Co
31/10/2024	13h00	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:OGN	Organon and Co
31/10/2024	12h30	Business Wire	Organon Reports Results for the Third Quarter Ended September 30, 2024	NYSE:OGN	Organon and Co
31/10/2024	05h02	Business Wire	La FDA des États-Unis accepte la demande de licence de produits biologiques (BLA) pour HLX14, le candidat biosimilaire de PROLIA/XGEVA (denosumab)	NYSE:OGN	Organon and Co
30/10/2024	11h00	Business Wire	US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)	NYSE:OGN	Organon and Co
29/10/2024	17h22	Business Wire	Organon vollzieht Übernahme von Dermavant einschließlich der innovativen dermatologischen Therapie VTAMA® (Tapinarof) Creme, 1 %	NYSE:OGN	Organon and Co
29/10/2024	17h22	Business Wire	オルガノン、ダーマバントの買収を完了し、画期的な皮膚科治療薬VTAMA®（タピナロフ）クリーム1％を取得	NYSE:OGN	Organon and Co
29/10/2024	17h22	Business Wire	Organon conclut l'acquisition de Dermavant, qui propose notamment un traitement dermatologique innovant : la crème VTAMA® (tapinarof) 1 %	NYSE:OGN	Organon and Co
28/10/2024	14h25	Business Wire	Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%	NYSE:OGN	Organon and Co
28/10/2024	14h25	GlobeNewswire Inc.	Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%	NYSE:OGN	Organon and Co
09/10/2024	13h30	Business Wire	Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024	NYSE:OGN	Organon and Co
08/10/2024	14h01	PR Newswire (Canada)	Organon Canada Promotes Geneviève Gauthier as Executive Director, Corporate Affairs and Community Engagement and Appoints Jeffrey Malawski as Executive Director, Women's Health and Established Brands	NYSE:OGN	Organon and Co
08/10/2024	14h01	PR Newswire (Canada)	Organon Canada promeut Geneviève Gauthier au poste de directrice exécutive, Affaires corporatives et Engagement communautaire, et nomme Jeffrey Malawski comme directeur exécutif, Santé des femmes et marques établies	NYSE:OGN	Organon and Co
30/09/2024	21h26	Business Wire	パージェタ（Perjeta®）（ペルツズマブ）バイオシミラー候補HLX11の第3相比較臨床試験で主要評価項目を達成	NYSE:OGN	Organon and Co
30/09/2024	18h17	Business Wire	Primärer Endpunkt in Phase-3-Vergleichsstudie zu Perjeta® (Pertuzumab) Biosimilar-Kandidat HLX11 erreicht	NYSE:OGN	Organon and Co
30/09/2024	17h59	Business Wire	Critères principal atteint dans une étude clinique comparative de phase 3 sur le candidat biosimilaire HLX11 du Perjeta® (pertuzumab)	NYSE:OGN	Organon and Co
30/09/2024	12h00	Business Wire	Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11	NYSE:OGN	Organon and Co
26/09/2024	15h50	PR Newswire (Canada)	Organon Canada and the Alberta Women's Health Foundation unite to raise awareness and advocate for universal access to contraception in Canada	NYSE:OGN	Organon and Co
26/09/2024	15h49	PR Newswire (Canada)	Organon Canada et l'Alberta Women's Health Foundation s'unissent pour accroître la sensibilisation et prôner l'accès universel à la contraception au Canada	NYSE:OGN	Organon and Co
23/09/2024	22h21	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:OGN	Organon and Co
19/09/2024	20h30	Business Wire	オルガノンがDermavantを買収し、画期的な皮膚科治療薬VTAMA®（タピナロフ）クリーム1%を取得	NYSE:OGN	Organon and Co

Showing the most relevant articles for your search:NYSE:OGN

1 2 3 4 5 6 7 8 9 10 Next >>

Deutsche Telekom

Deutsche Telekom (QX)

Euro vs US Dollar

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen